  Factors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn's disease patients (BELCRO); ; et al in Gastroenterology (2012, May) Detailed reference viewed: 8 (0 ULg)Safety And Cost Of Infliximab For The Treatment Of Belgian Pediatric Patients With Crohn’s Disease; ; et al in Acta Gastro-Enterologica Belgica (2012, February) Detailed reference viewed: 10 (3 ULg) Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.; ; et al in Acta Gastro-Enterologica Belgica (2012), 75(4), 425-31 Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in ... [more ▼] Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in Belgian pediatric Crohn's disease patients. All patients on infliximab as part of the present or past treatment for Crohn's Disease until January 1st 2011 were selected from an existing database. Information on disease phenotype, medication and adverse events were extracted. Adverse events occurred in 25.9% of patients exposed to infliximab of which 29.6% were severe. In total 31.7% of patients stopped infliximab therapy. The main reasons for discontinuation were adverse events in 45.4% and loss of response in 30.3%. No malignancies or lethal complications occurred over this 241 patient year observation period. Immunomodulators were concomitant medication in 75% of patients and were discontinued subsequently in 38.4% of them. The cost of infliximab infusions per treated patient per year in the Belgian health care setting is approximately 9 474 euro, including only medication and hospital related costs. Even though infliximab is relatively safe in pediatric CD on the short term, close follow-up and an increased awareness of the possible adverse reactions is highly recommended. Adverse reactions appeared in 25.9% of all patients and were the main reason for discontinuation. Treatment cost has to be balanced against efficacy and modifications in disease course. In the Belgian health care system, the medication is available to all patients with moderate to severe CD. [less ▲] Detailed reference viewed: 1 (0 ULg)Safety And Cost Of Infliximab For The Treatment Of Belgian Pediatric Patients With Crohn’s Disease; ; et al in Journal of Crohn’s and Colitis (2012) Detailed reference viewed: 18 (1 ULg)Factors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn’s disease patients (BELCRO); ; et al in Acta Gastro-Enterologica Belgica (2012) Detailed reference viewed: 12 (0 ULg)Profile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis; ; et al in Gastroenterology (2011), 140(5), 787 Detailed reference viewed: 10 (2 ULg)Profile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis; ; et al in Acta Gastro-Enterologica Belgica (2011), 74 Detailed reference viewed: 3 (1 ULg)Profile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis; ; et al in Journal of Crohn’s and Colitis [=JCC] (2011), 5(1), 156 Detailed reference viewed: 10 (0 ULg)Profile of Belgian Pediatric Crohn's Disease Patients: Presentation and diagnostic features; ; et al in Gastroenterology (2011), 140(5), 786 Detailed reference viewed: 10 (1 ULg)Profile of Belgian Pediatric Crohn's Disease Patients: Presentation and diagnostic features; ; et al in Acta Gastro-Enterologica Belgica (2011), 74 Detailed reference viewed: 9 (2 ULg)Profile of Belgian Pediatric Crohn's Disease Patients: Presentation and diagnostic features; ; et al in Journal of Crohn’s and Colitis [=JCC] (2011), 5(1), 155 Detailed reference viewed: 5 (1 ULg)Capsule Endoscopy in paediatrics: multicentric Belgian study; ; et al in Acta Gastro-Enterologica Belgica (2007), 70(1, JAN-MAR), 11-14 Bacground and study aims : Capsule Endoscopy (CE) is a non-invasive procedure for evaluating small bowel disease. Data concerning children are scarce. The aim of the present report was to review all ... [more ▼] Bacground and study aims : Capsule Endoscopy (CE) is a non-invasive procedure for evaluating small bowel disease. Data concerning children are scarce. The aim of the present report was to review all paediatric cases investigated by CE in Belgium. Patients and methods : The seven Belgian academic hospitals using the CE device (Given) were asked to collect information on CE performed in patients <= 18 years. Main indications for performing VCE, former radiological and endoscopic procedures were collected, as well as final diagnosis and clinical impact of VCE findings. Results : From November 2002 until December 2005, VCE was performed in 17 children (mean age : 11.9 years, range : 5-18). Indications were occult gastro-intestinal bleeding (OGIB) and/or iron deficiency anaemia (IDA) (10 cases) and chronic and/or recurrent abdominal pain (7 cases). Mean duration of symptoms was 8.6 months. The mean number of endoscopic and radiological procedures before performing CE was 4.2 per patient. Detected lesions were ulcerations (6 cases), jejunal varices (1), ileo-ileal invagination (2), active bleeding (1), and normal findings (7). In the indication of OGIB/IDA, relevant findings having an impact on the diagnosis were found in 60% of the cases. In the group with chronic and recurrent abdominal pain, CE brought relevant findings in 43%. CE findings had an impact on therapy in 44% of the patients. Conclusions : CE could be a useful tool for clinical work-up of difficult paediatric cases, not only in the indication of IDA/OGIB, but also for selected cases of recurrent abdominal pain, but prospective controlled trials including emerging techniques like CT enterography are mandatory. [less ▲] Detailed reference viewed: 14 (0 ULg) |
||
